Celgene Sells Otezla to Advance its Sale to Bristol-Myers Squibb

Amgen (NASDAQ: AMGN) has agreed to take Otezla (apremilast) off of Celgene Corporation‘s (NASDAQ: CELG) hands. The Federal Trade Commission ruled the drug had to be divested due to concerns over competition with Bristol-Myers Squibb‘s (NYSE: BMY) pipeline. Bristol-Myers announced it was buying Celgene last January for $74 billion. In this deal, Amgen gains the worldwide […]

Healthcare Dollar Volume Exploded in January

Dollar volume for healthcare deals announced in January was ridiculous, topping $90 billion. We don’t see figures like that in most quarters. The outsized total results from a single deal, of course. Bristol-Myers Squibb’s (NYSE: BMY) $74 billion acquisition of Celgene Corp. (NASDAQ: CELG) made up 81% of the month’s total. Suffice it to say […]


Biotechnology Gets the Usual January Boost

The Biotechnology sector roared to life in 2017, posting a record 209 transactions. That’s 20% higher than the 174 deals announced in 2016. The previous record for the sector was set in 2009, with 193 transactions announced in the space. Spending for those 209 deals in 2017 didn’t set new records, but did post an […]